Apple's roughly 40 times trailing and 37 times forward earnings make the shares too expensive ahead of next week's results. A short looks reasonable, though a sell-the-news reaction after earnings remains uncertain. x.com  x.com 

C3is trades far below its cash: about $48M on the books against a float of roughly 1.5-2 million shares implies $24-32 a share, yet the stock is near $1.5, and the company is now profitable. It was a dilution machine while acquiring its fleet, but the story looks to be changing. Short interest is 55%, cost to borrow 146%, few shares remain to short, and institutional ownership rose. About 450,000-500,000 warrants at $1.51 and $2.44 remain, making $2.44 the next target. x.com  x.com  x.com  x.com  … Show more

Apple's price tag isn't justified by its earnings growth or its lack of innovation. Analysts expect $153B of net income by 2028 versus $104B in 2024, roughly a 10% CAGR, so good returns need the elevated multiple to hold or rise toward 50x. Apple hasn't innovated since AirPods, Siri fumbled its door to AI, and its dominance rests on no one wanting to compete while consumer tastes shift fast, as BlackBerry showed. The stock isn't expected to crash, but likely won't rise over the next five years. … Show more

China SXT Pharmaceuticals is a short-squeeze candidate: short interest exceeds 20%, institutional ownership exceeds 100%, no shares are left to borrow and the cost to borrow is over 500%. It has the same setup as other low-float, high-short-interest plays; after coiling all day, a pop on incoming volume is only a matter of time because shorts are trapped. x.com  x.com 

Apple has failed so badly at AI that there is little reason to own more of the stock. It should have been the biggest and best in AI right out of the gate and has no excuse for falling behind. x.com  x.com 

Apple's 9% drop on weaker guidance is negligible for a long-term holder. It beat earnings, but guidance was hurt by significant DRAM and NAND price inflation and supply constraints, which also suggests the memory supercycle is not over. Apple is one of the names worth holding long term, and Alphabet's earnings gap-down recovered within days. x.com 

Apple lags on AI and suffers from AI-driven cost shocks to components such as memory and storage. x.com 

Apple is worth considering as a short because its rise is driven by flows, not fundamentals. Money rotating out of AI spenders has gone into Apple precisely because it is not spending on AI, even after a poor quarter. Growth is slowing and the company has not innovated much in 10-15 years, living off price increases, buybacks and passive index flows. It now trades at 40x earnings at an all-time high. x.com 

Cellebrite is unlikely to return to 25% ARR growth, so its cheap valuation will not expand until revenue reaccelerates. It depends too heavily on the US government, unlike Axon, which is diversifying into states and commercial. Its edge was unlocking iPhones, but its evidence-management platform is sticky without a moat, and breaching phones gets harder with each iOS version. Repeated misses with new excuses are worrying, even if guidance looks sandbagged and deal delays are only ~6 weeks. x.com  … Show more